Plant ID: NPO21507
Plant Latin Name: Ephedra intermedia
Taxonomy Genus: Ephedra
Taxonomy Family: Ephedraceae
NCBI TaxonomyDB:
173278
Plant-of-the-World-Online:
n.a.
Antiasthmatic; Antidote; Antihydrotic; Diaphoretic; Diuretic; Vasoconstrictor; Vasodilator
India; China
TSHR; NMUR2; | |
ADRA2A; | |
CES1; TDP1; BLM; PKM; ALOX12; CBR1; HSD17B10; ALOX15; APEX1; CES2; | |
CHRNA3; CHRNA4; | |
PPARA; PPARD; | |
ALOX5; | |
DPP4; | |
TLR2; | |
HIF1A; | |
LMNA; FABP3; FABP5; FABP2; FABP4; THPO; | |
SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Enzyme_unclassified | CES1 | Acyl coenzyme A:cholesterol acyltransferase | P23141 | CHEMBL2265 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | CBR1 | Carbonyl reductase [NADPH] 1 | P16152 | CHEMBL5586 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | CES2 | Carboxylesterase 2 | O00748 | CHEMBL3180 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nicotinic acetylcholine receptor | CHRNA3 | Neuronal acetylcholine receptor subunit alpha-3 | P32297 | CHEMBL3068 |
Nicotinic acetylcholine receptor | CHRNA4 | Neuronal acetylcholine receptor protein alpha-4 subunit | P43681 | CHEMBL1882 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
Serine protease | DPP4 | Dipeptidyl peptidase IV | P27487 | CHEMBL284 |
Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 7.468E-09 | 1.162E-05 | CHRNA4, DPP4, HIF1A, LMNA, PKM, PPARA, PPARD, TLR2 |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 7.656E-08 | 8.148E-05 | FABP2, FABP3, FABP4, FABP5 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 8.232E-08 | 8.148E-05 | CYP1A2, CYP2C19, CYP2C9 |
BP | GO:0007610; behavior | GO:0035095; behavioral response to nicotine | 1.439E-07 | 1.306E-04 | CHRNA3, CHRNA4, PPARA |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.891E-07 | 1.525E-04 | ALOX12, ALOX15, ALOX5, TLR2 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.230E-07 | 1.734E-04 | ALOX12, ALOX15, ALOX5, CYP1A2, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.917E-07 | 3.692E-04 | CYP1A2, CYP2C19, CYP2C9 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 8.994E-07 | 6.120E-04 | CYP1A2, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.162E-06 | 7.670E-04 | CES1, CES2, CYP1A2, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 2.279E-06 | 1.341E-03 | ALOX12, ALOX15, ALOX5 |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 2.659E-06 | 1.379E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 2.659E-06 | 1.379E-03 | ALOX12, ALOX15 |
BP | GO:0051179; localization | GO:0015908; fatty acid transport | 4.418E-06 | 2.237E-03 | FABP3, NMUR2, PPARA, PPARD |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.383E-06 | 2.548E-03 | CYP1A2, CYP2C19, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 7.968E-06 | 3.470E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 7.968E-06 | 3.470E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0047374; methylumbelliferyl-acetate deacetylase activity | 7.968E-06 | 3.470E-03 | CES1, CES2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.592E-05 | 5.876E-03 | CYP1A2, CYP2C9 |
BP | GO:0007610; behavior | GO:0007610; behavior | 2.353E-05 | 8.133E-03 | CHRNA3, CHRNA4, DPP4, HIF1A, NMUR2, PPARA, TLR2 |
BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 2.651E-05 | 8.745E-03 | ALOX12, ALOX15 |
CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 1.736E-04 | 3.708E-02 | ADRA2A, CHRNA3, CHRNA4, TLR2, TSHR |
CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 1.737E-04 | 3.708E-02 | SMN1, SMN2 |
CC | GO:0032991; macromolecular complex | GO:0032797; SMN complex | 2.050E-04 | 4.178E-02 | SMN1, SMN2 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.108E-04 | 2.990E-03 | CYP2C9, ALOX15 |
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 3.994E-04 | 3.448E-03 | CHRNA3, ADRA2A, TSHR |
09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 4.167E-04 | 3.448E-03 | FABP4, TSHR |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 5.108E-04 | 3.448E-03 | CYP2C9, ALOX15 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.654E-03 | 8.931E-03 | CYP2C9, ALOX15 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | CHRNA3; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | CHRNA3; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA2A; |